

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY<sup>®</sup>

## EDITORIAL

### Medical-Device Reprocessing

MICHELLE J. ALFA, PhD

496

## ORIGINAL ARTICLES

### Cleaning of Blood-Contaminated Reprocessed Angiographic Catheters and Spinal Needles

THEREZA CHRISTINA VESSONI PENNA, PhD; CARLOS AUGUSTO M. FERRAZ, PhD

499

### Pathogenic Organisms Associated With Artificial Fingernails Worn by Healthcare Workers

SARA A. HEDDERWICK, MRCP; SHELLY A. McNEIL, MD;  
MICHAEL J. LYONS, PA, CIC; CAROL A. KAUFFMAN, MD

505

### Nosocomial Infections in Combined Medical-Surgical Intensive Care Units in the United States

MICHAEL J. RICHARDS, MBBS, FRACP; JONATHAN R. EDWARDS, MS; DAVID H. CULVER, PhD;  
ROBERT P. GAYNES, MD; THE NATIONAL NOSOCOMIAL INFECTIONS SURVEILLANCE SYSTEM

510

### Activity of an Alcohol-Based Hand Gel Against Human Adeno-, Rhino-, and Rotaviruses Using the Fingerpad Method

SYED A. SATTAR, PhD; MAKONNEN ABEBE, MSc; ANGELA J. BUETI, BSc;  
HANUMAN JAMPANI, PhD; JERRY NEWMAN, PhD; STEVEN HUA, MSc

516

### Prevalence and Determinants of Fecal Colonization With Vancomycin-Resistant *Enterococcus* in Hospitalized Patients in The Netherlands

NICOLE VAN DEN BRAAK, MSc; ALEWIJN OTT, MD; ALEX VAN BELKUM, PhD;  
JAN A.J.W. KLUYTMANS, MD; JOHANNES G.M. KOELEMAN, MD; LODEWIJK SPANJAARD, MD;  
ANDREAS VOSS, MD; ANNEMARIE J.L. WEERSINK, MD; CHRISTINA M.J.E. VANDENBROUCKE-GRAULS, MD;  
ANTON G.M. BUITING, MD; HENRI A. VERBRUGH, MD; HUBERT P. ENDTZ, MD

520

## SHEA POSITION PAPER

### Antimicrobial Use in Long-Term-Care Facilities

LINDSAY E. NICOLLE, MD; DAVID W. BENTLEY, MD; RICHARD GARIBALDI, MD;  
ELLEN G. NEUHAUS, MD; PHILIP W. SMITH, MD; THE SHEA LONG-TERM-CARE COMMITTEE

537

Continued inside.

Are You Doing All You Can  
to Stop Methicillin-Resistant  
*Staphylococcus aureus*  
Outbreaks Where They Originate...

The Nares

- *Bactroban* Nasal is indicated for eradication of nasal colonization with methicillin-resistant *S. aureus* (MRSA) in adult patients and healthcare workers as part of a comprehensive infection control program to reduce the risk of infection among high-risk patients during MRSA outbreaks.<sup>1</sup>
- In a hospital study, *Bactroban* Nasal contributed to a dramatic reduction in MRSA infections and vancomycin costs during an outbreak.<sup>2</sup>

Single-use tube  
(actual size)



**BACTROBAN® NASAL (mupirocin calcium ointment), 2% Brief summary. For complete prescribing information, see package insert.**

**INDICATIONS AND USAGE**

*Bactroban* Nasal is indicated for eradication of nasal colonization with methicillin-resistant *Staphylococcus aureus* in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of methicillin-resistant *S. aureus* infection during institutional outbreaks of infections with this pathogen.

**NOTE:**

- (1) There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with *S. aureus*.
- (2) There are insufficient data at this time to recommend use of *Bactroban* Nasal for general prophylaxis of any infection in any patient population.
- (3) Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2 to 4 days after therapy was completed. Approximately 30% recolonization was reported in one domestic study within 4 weeks after completion of therapy. These eradication rates were clinically and statistically superior to those reported in subjects/patients in the vehicle-treated arms of the adequate and well-controlled studies. Those treated with vehicle had eradication rates of 5% to 30% at 2 to 4 days post-therapy with 85% to 100% recolonization within 4 weeks.

**CONTRAINDICATIONS**

*Bactroban* Nasal is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

**WARNINGS**

**AVOID CONTACT WITH THE EYES.** Application of *Bactroban* Nasal to the eye under testing conditions has caused severe symptoms such as burning and tearing. These symptoms resolved within days to weeks after discontinuation of the ointment.

In the event of a sensitization or severe local irritation from *Bactroban* Nasal, usage should be discontinued.

**PRECAUTIONS**

**General:** As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. (See **DOSE AND ADMINISTRATION** in complete prescribing information.)

**Information for Patients:** Patients should: apply approximately one-half of the ointment from the single-use tube directly into one nostril and the other half into the other nostril; avoid contact of the medication with the eyes; discard the tube after using; press the sides of the nose together and gently massage after application to spread the ointment throughout the inside of the nostrils; and discontinue using *Bactroban* Nasal and call a health care practitioner if sensitization or severe local irritation occurs.

**Drug Interactions:** The effect of the concurrent application of intranasal mupirocin calcium and other intranasal products has not been studied. Do not apply mupirocin calcium ointment, 2% concurrently with any other intranasal products.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Long-term studies in animals to evaluate carcinogenic potential of mupirocin calcium have not been conducted. Results of the following studies performed with mupirocin calcium or mupirocin sodium *in vitro* and *in vivo* did not indicate a potential for mutagenicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, *Salmonella* reversion test (Ames), *Escherichia coli* mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice. Reproduction studies were performed in rats with mupirocin administered subcutaneously at doses up to 40 times the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m<sup>2</sup> basis and revealed no evidence of impaired fertility from mupirocin sodium.

**Pregnancy: Teratogenic Effects. Pregnancy Category B.** Reproduction studies have been performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 65 and 130 times, respectively, the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m<sup>2</sup> basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

**Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when *Bactroban* Nasal is administered to a nursing woman.

**Pediatric Use:** Safety in children under the age of 12 years has not been established. (See **CLINICAL PHARMACOLOGY** in complete prescribing information.)

**ADVERSE REACTIONS**

**Clinical Trials:** In clinical trials, 210 domestic and 2,130 foreign adult subjects/patients received *Bactroban* Nasal ointment. Less than 1% of domestic or foreign subjects and patients in clinical trials were withdrawn due to adverse events. In domestic clinical trials, 17% (36/210) of adults treated with *Bactroban* Nasal ointment reported adverse events thought to be at least possibly drug-related. The incidence of adverse events that were reported in at least 1% of adults enrolled in domestic clinical trials were as follows: headache, 9%; rhinitis, 6%; respiratory disorder, including upper respiratory tract congestion, 5%; pharyngitis, 4%; taste perversion, 3%; burning/stinging, 2%; cough, 2%; and pruritus, 1%.

The following events thought possibly drug-related were reported in less than 1% of adults enrolled in domestic clinical trials: blepharitis, diarrhea, dry mouth, ear pain, epistaxis, nausea and rash. All adequate and well-controlled clinical trials have been performed using *Bactroban* Nasal ointment, 2% in one arm and the vehicle ointment in the other arm of the study.

**OVERDOSAGE**

Following single or repeated intranasal applications of *Bactroban* Nasal to adults, no evidence for systemic absorption of mupirocin was obtained.

Manufactured by **DPT Laboratories**, San Antonio, TX 78215  
Distributed by **SmithKline Beecham Pharmaceuticals**, Philadelphia, PA 19101  
BRS-BN:L3

## Fit Test TB Masks the Easy Way!

...with the PORTACOUNT® Plus Respirator Fit Tester  
and N95-Companion™ from TSI.

- Quantitatively fit tests any N95 disposable respirator.
- Easy to use...any other way is the hard way!
- Provides confidence in fit test results.
- Replaces subjective and tedious Bitrex and saccharin methods.
- Complies with OSHA's TB guidelines.
- Windows®-based software automates fit tests and maintains records.
- Also fit tests respirators used by hospital maintenance workers.



**TSI Incorporated  
Health and Safety Instruments**

P.O. Box 64394 Website: [www.tsi.com](http://www.tsi.com)  
St. Paul, MN 55164 USA E-mail: [health.safety@tsi.com](mailto:health.safety@tsi.com)  
Tel: **800 926 8378**  
or 651 490 2760  
Fax: 651 490 2704



# Mothers. Spouses. (maybe) Medical Matrix.

What do they have in common? You place your trust in them. When searching the Internet for credible medical information, you need a resource you can trust. *The Lancet* quotes that "Medical Matrix is the most comprehensive compendium of reliable medical information on the Internet."

## MEDICAL MATRIX LLC

<http://www.medmatrix.org>

The largest, peer-reviewed directory to the medical Internet.

Free registration.

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

## EDITORIAL ADVISORY BOARD

### EDITORIAL OFFICES

Vanderbilt University School of Medicine  
A-1131 Medical Center North  
Nashville, TN 37232-2637  
(615) 343-1095; (615) 343-1882 (FAX)  
Email: iche@mcmail.vanderbilt.edu

### EDITOR

Michael D. Decker, MD, MPH

### MANAGING EDITOR

Susan Cantrell

### STATISTICAL EDITOR

Beverly G. Mellen, PhD

### SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

### ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

### SECTION EDITORS

#### Beyond Infection Control:

#### The New Hospital Epidemiology

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

#### Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

#### Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

#### From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

#### Information Management

John A. Sellick, DO

Buffalo, New York

#### The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

#### Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

#### Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

#### Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

#### SHEA News

Andreas Voss, MD, PhD

Nijmegen, The Netherlands

#### Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

#### Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

#### Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

- Jacques F. Acar, MD Paris, France  
J. Wesley Alexander, MD Cincinnati, Ohio  
Paul Arnow, MD Chicago, Illinois  
Graham A.J. Ayliffe, MD Birmingham, United Kingdom  
Neil L. Barg, MD Yakima, Washington  
Elizabeth Ann Bolyard, RN, MPH, CIC Atlanta, Georgia  
John M. Boyce, MD Providence, Rhode Island  
Professor Dr. Ilja Braveny Munich, Germany  
Christian Brun-Buisson, MD Creteil, France  
Charles Bryan, MD Columbia, South Carolina  
Donald E. Craven, MD Boston, Massachusetts  
Sue Crow, MSN, RN, CIC Shreveport, Louisiana  
Franz Daschner, MD Freiburg, Germany  
Leigh G. Donowitz, MD Charlottesville, Virginia  
Charles E. Edmiston, Jr., PhD Milwaukee, Wisconsin  
Theodore C. Eickhoff, MD Denver, Colorado  
Bruce Farber, MD Manhasset, New York  
Victoria J. Fraser, MD St. Louis, Missouri  
Peter C. Fuchs, MD, PhD Black Butte, Oregon  
Richard A. Garibaldi, MD Farmington, Connecticut  
Robert Gaynes, MD Atlanta, Georgia  
Velvi Greene, PhD, MPH Beer Sheva, Israel  
David W. Gregory, MD Nashville, Tennessee  
David K. Henderson, MD Bethesda, Maryland  
Peter N.R. Heselstine, MD Los Angeles, California  
Karen Hoffmann, RN, CIC, MS Chapel Hill, North Carolina  
Marguerite McMillan Jackson, RN, PhD San Diego, California  
Janine Jagger, MPH, PhD Charlottesville, Virginia  
William R. Jarvis, MD Atlanta, Georgia  
Douglas S. Kernodle, MD Nashville, Tennessee  
Robert H. Latham, MD Nashville, Tennessee  
Lewis B. Lefkowitz, MD Nashville, Tennessee  
Hsieh-Shong Leu, MD, MSc Taipei, Taiwan  
Jack Levy, MD Brussels, Belgium  
Victor Lorian, MD Bronx, New York  
Dennis G. Maki, MD Madison, Wisconsin  
William J. Martone, MD Bethesda, Maryland  
Allison McGeer, MD Toronto, Ontario, Canada  
John E. McGowan, Jr., MD Atlanta, Georgia  
Jonathan L. Meakins, MD, DSc Montreal, Quebec, Canada  
Robert R. Muder, MD Pittsburgh, Pennsylvania  
Joseph M. Mylotte, MD, CIC Buffalo, New York  
Lindsay Nicolle, MD Winnipeg, Manitoba, Canada  
Juhani Ojajarvi, MD Helsinki, Finland  
Michael T. Osterholm, PhD, MPH Minneapolis, Minnesota  
Jan Evans Patterson, MD San Antonio, Texas  
Sindy M. Paul, MD Trenton, New Jersey  
Michael A. Pfaller, MD Iowa City, Iowa  
Samuel Ponce de Leon, MD, MSc Mexico City, Mexico  
Isaam Raad, MD Houston, Texas  
Manfred L. Rotter, MD, DipBact Vienna, Austria  
Theodore Sacks, MD Jerusalem, Israel  
William E. Scheckler, MD Madison, Wisconsin  
Kent Sepkowitz, MD New York City, New York  
Denis Spelman, MD Prahran Victoria, Australia  
Michael L. Tapper, MD New York, New York  
Clyde Thornsberry, PhD Brentwood, Tennessee  
Professor Leonid P. Titov Minsk, Republic of Belarus  
Timothy R. Townsend, MD Millwood, Virginia  
Antoni Trilla, MD, PhD Barcelona, Spain  
Professor Wang Shu-Qun Beijing, People's Republic of China  
J. John Weems, Jr., MD Greenville, South Carolina  
Robert A. Weinstein, MD Chicago, Illinois  
Professor Dr. W. Weuffen Greifswald, Germany  
Sergio B. Wey, MD São Paulo, Brazil  
Rebecca Wurtz, MD Evanston, Illinois

### SLACK Incorporated

6900 Grove Road  
Thorofare, New Jersey 08086  
(856) 848-1000

#### Executive Vice President/Group Publisher

Richard N. Roash

#### Publisher

John C. Carter

#### Editorial Director

Jennifer Kilpatrick

#### Production Editor

Shirley P. Strunk, ELS

#### Assistant Editor

Eileen C. Anderer

#### Editorial Assistant

Christine C. Good

#### Circulation Manager

Lester J. Robeson, CCCP

#### Production Director

Christine Malin

#### Production Coordinator

Joanne Patterson

#### Publishing Director/ Advertising

Wayne McCourt

#### Pharmaceutical Group Sales Director

Michael LoPresti

#### Advertising Sales Representative

Tina Panna

#### Advertising Sales Coordinator

Lori Souder

#### Classified/Recruitment Sales Manager

Kelly Wark

#### Classified/Recruitment Sales Representative

Stacey Goldberg

Win. Destroy.  
You Can  
Declare War.



Win. Scrub. Win.  
Or You Can  
Declare Victory.

Arm yourself with **PREVACARE\*** Antimicrobial Hand Gel.  
A waterless product that combines persistent antimicrobial  
activity with skin moisturizers for use between hand washes.

Here's the weapon your facility needs to help win the war against nosocomial infections.

PREVACARE\* Antimicrobial Hand Gel is a unique, patented waterless surgical scrub and healthcare personnel handwash that demonstrates persistent antimicrobial activity between uses. PREVACARE\* Antimicrobial Hand Gel eliminates 99.99% of pathogenic organisms in 15 seconds or less without water or towels, yet is gentle enough for frequent hand washes.

Declare victory over nosocomial infections with help from PREVACARE\* Antimicrobial Hand Gel.

To learn more about this product or the complete line of Johnson & Johnson Medical Skin Care products, call 1-800-255-2500. Or visit our website at [www.prevacare.com](http://www.prevacare.com)



**Johnson & Johnson**

**MEDICAL**

Division of Ethicon, Inc.

Win

\*Trademark © JJM 2000 Arlington, Texas 76004-3130

<https://doi.org/10.1017/S0195941700043046> Published online by Cambridge University Press



The Society for Healthcare Epidemiology of America

## 2000 SHEA/CDC Training Course in Hospital Epidemiology

### Program

The program will be held October 14-17, 2000 at the Cincinnati Marriott at RiverCenter, Covington, Kentucky. Timothy W. Lane, M.D., Julie Gerberding, M.D., and Gina Pugliese, R.N., M.S., will co-chair the program. This program, developed by the Society for Healthcare Epidemiology of America (SHEA), and the Centers for Disease Control and Prevention (CDC), is intended for infectious disease fellows and new hospital epidemiologists. It emphasizes hands-on exercises in which participants work in small groups to detect, investigate, and control epidemiological problems encountered in the hospital setting. These work sessions are supplemented with lectures and seminars covering fundamental aspects of hospital epidemiology and surveillance, epidemic investigation, transmission and control of nosocomial infections, disinfection and sterilization, employee health, isolation systems, regulatory compliance, and quality improvement.

### Who Should Attend

You should attend if you are a hospital epidemiologist or an infection control practitioner or if you are looking for a course that will provide you with the most current information concerning infection control practices and epidemiological methods in health care. This fundamental program will provide you with opportunities to find solutions to real situations that will occur in the hospital setting. Intensive problem solving sessions are supplemented with lectures and seminars presented by leading authorities.

### Scholarships

Scholarships in the amount of \$1,000 will be awarded to infectious disease fellows for the program to defray the special course fee for fellows of \$400 and expenses incurred in attending the training program.

Interested fellows must submit a letter of no more than one page describing why they would like to have additional training in hospital epidemiology. A letter from the fellow's program director outlining the applicant's qualifications and suitability

for the course also is required. The deadline for receipt of scholarship applications for the course is September 1, 2000. The SHEA Educational Activities Committee will select the scholarship recipients based on review of these letters. Winners will be notified in late September.

### Nominations

Please send scholarship applications to:  
Timothy W. Lane, M.D.  
c/o The Society for Healthcare Epidemiology of America  
19 Mantua Road  
Mt. Royal, NJ 08061

### Fees

Individual Registrants	\$575
Fellows in Infectious Disease	\$400

### Credits

The Society for Healthcare Epidemiology of America (SHEA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The Society for Healthcare Epidemiology of America designates this continuing education activity for up to 23 hours in Category 1 of the Physician's Recognition Award of the American Medical Association.

### General Course Information

Information regarding the schedule, hotel and travel accommodations, discount airfare, and course fees are available from SHEA (856) 423-7222. Note that application for a scholarship does not constitute enrollment in the program. This must be done separately.

Scholarship Awards provided in part by an educational grant from Pfizer Pharmaceuticals.



Labo • NHO • Pratt • Roerig • Specialty  
U.S. Pharmaceuticals Group

# ONLY SOURCE for all 12 Guidelines

Includes New HIV <sup>and</sup> HCV Post-Exposure Prophylaxis

### Twelve Guidelines (1984 - Present)

Catheter-Associated Urinary Tract Infections	Surgical Site Infection
Handwashing and Environmental Control	Isolation Precautions in Hospitals
HIV and HBV Exposure-Prone Procedures	Pneumonia
Tuberculosis	Vancomycin Resistance
IV Device-Related Infections	Infection Control in Healthcare Personnel
HIV Postexposure Prophylaxis	Occupational Exposure to Hepatitis C Virus

and Index of SHEA Position Papers  
Foreword by Julia S. Garner, RN, MN

CDC Guidelines  
for Surveillance  
Prevention & Control  
of Nosocomial Infections



All In One Single Volume for only  
**\$99.<sup>00</sup>\***

Order Today - Call **1-800-552-0076**

International Orders Call 414-884-4532

Mention this ad for 10% discount!

**www.ETNAComm.com**

\*Plus shipping & handling.

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY<sup>®</sup>

## CONTENTS

Continued from cover

### CONCISE COMMUNICATIONS

#### Use of Spoligotype Analysis to Detect Laboratory Cross-Contamination

BETH NIVIN, MPH; JEFFREY DRISCOLL, PhD; TOM GLASER, MTA; PABLO BIFANI, PhD; SONAL MUNSIFF, MD

525

#### Epidemiology of Nosocomial Outbreaks: 14-Year Experience at a Tertiary-Care Center

LUIS OSTROSKY-ZEICHNER, MD; ROSA BAEZ-MARTINEZ, RN;  
M. SIGFRIDO RANGEL-FRAUSTO, MD, MSc; SAMUEL PONCE-DE-LEÓN, MD, MSc

527

#### Transient Detection of Plasma HIV-1 RNA During Postexposure Prophylaxis

VINCENZO PURO, MD; GIUSEPPE CALCAGNO, MD; MARCO ANSELMO, MD; GISELLA BENVENUTO, MD;  
DARIA TRABATTONI, BSc; MARIO CLERICI, MD; GIUSEPPE IPPOLITO, MD

529

#### A Pilot Study on Infection Control in 10 Randomly Selected European Hospitals: Results of a Questionnaire Survey

DESIRÉE J.M.A. BEAUJEAN, MSc; ANNEMARIE J.L. WEERSINK, MD;  
ANNET TROELSTRA, MD; JAN VERHOEF, MD, PhD

531

#### Nosocomial Infections in a New Medical Center, Turkey

BENGÜL DURMAZ, PhD; RIZA DURMAZ, PhD; BARIŞ ÖTLÜ, BS; EMINE SÖNMEZ, MD

534

### LETTERS TO THE EDITOR

#### Costs and Benefits of Measures to Prevent Needlestick Injuries in a University Hospital (with reply)

FRANKLIN N. LAUFER, PhD; LINDA CHIARELLO, RN, MS; ISABELLE DURAND-ZALESKI, MD, PhD

494

#### Evaluation of Hospital Infection Rates and Control Measures in a Cardiac Surgery Hospital: 10 Years' Experience

CELY SAAD ABBOUD, MD; ANA LÚCIA FIRMINO, RN

494

### MEDICAL NEWS

GINA PUGLIESE, RN, MS; MARTIN S. FAVERO, PhD

546

### SHEA NEWS

ANDREAS VOSS, MD, PhD

552

To view abstracts of these articles,  
visit us on the Internet at <http://www.slackinc.com/general/icbe>

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

**PUBLISHER:** Infection Control and Hospital Epidemiology (ISSN-0899-823X, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (856) 848-1000.

**SHEA:** 19 Mantua Rd., Mt. Royal, NJ 08061; telephone, 856-423-0087; fax, 856-423-3420; e-mail address, sheahq@talley.com.

**COPYRIGHT 2000** The Society for Healthcare Epidemiology of America, Inc., and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Printed in the USA.

**SUBSCRIPTIONS:** Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$110.00; Two years-\$148.00; Three years-\$183.00; Institutional: One year-\$133.00; Two years-\$183.00; Three years-\$233.00. Fellows: \$55.00 per year with proof of training status. Canada: \$20.00 additional each year plus 7% for Canadian Goods & Services tax; Overseas surface, \$150.00 each year; Overseas air mail, \$195.00. Single copies of current issues may be obtained for \$15.00, United States and possessions; \$20.00 all other countries.

**INSTRUCTIONS TO AUTHORS:** Authors may submit manuscripts prepared in accordance with the 1997 revision of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." The Uniform Requirements has been published in several journals, including *Infect Control Hosp Epidemiol* 1997;18:457-464 and *Ann Intern Med* 1997;126:36-47. A digital version is available on our web site (<http://www.slackinc.com/general/icbehome.htm>). Submit to ICHE Editorial Offices, Vanderbilt University School of Medicine, A-1131 Medical Center North, Nashville, TN 37232-2637, USA. All submissions must be accompanied by copyright form(s) signed by all authors (see January issue or our web site).

**REPRINTS:** All requests to reprint or use material published herein should be addressed to Karen Lambertson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Karen Lambertson at (856) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$.15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

**CHANGE OF ADDRESS:** Notice should be sent to the publisher 6 weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Periodicals postage paid at Thorofare, New Jersey 08086-9447 and at additional mailing offices. POSTMASTER: Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

**INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY** is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, Laboratory Performance Information Exchange System, and RnDEX Top 100.